HCM - Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

• Hutchmed (China) ( NASDAQ: HCM ) said it began dosing in a phase 2 bridging study of tazemetostat in China to treat patients with relapsed/refractory follicular lymphoma (R/R FL).
• Tazemetostat is developed by Epizyme ( NASDAQ: EPZM ) and Hutchmed has an agreement with the Cambridge, Mass.-based company to develop and sell the drug in China, Hong Kong, Macau and Taiwan. Epizyme is in the process of being acquired by France's Ipsen.
• Hutchmed said that the main goal of the study is to evaluate the efficacy of tazemetostat to treat patients with R/R FL who have mutations in the EZH2 gene (Cohort 1).
• Meanwhile, the secondary goals is to check efficacy of the drug in treating patients with R/R FL who have EZH2 wild-type (Cohort 2) and to evaluate safety.
• Follicular lymphoma occurs when the body develops abnormal B lymphocytes, type of white blood cells.

For further details see: